First Trust Advisors LP decreased its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 50.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 18,372 shares of the biopharmaceutical company's stock after selling 19,071 shares during the period. First Trust Advisors LP's holdings in Celldex Therapeutics were worth $464,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. EverSource Wealth Advisors LLC raised its holdings in Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 878 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Celldex Therapeutics in the 4th quarter worth approximately $81,000. KBC Group NV raised its stake in shares of Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares in the last quarter. AlphaQuest LLC raised its stake in shares of Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock worth $108,000 after acquiring an additional 2,705 shares in the last quarter. Finally, Aristides Capital LLC purchased a new stake in Celldex Therapeutics during the fourth quarter valued at approximately $202,000.
Celldex Therapeutics Stock Performance
NASDAQ CLDX traded up $0.53 during trading hours on Thursday, reaching $19.47. The stock had a trading volume of 197,411 shares, compared to its average volume of 889,150. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The stock has a fifty day moving average of $18.90 and a 200 day moving average of $22.70. The stock has a market cap of $1.29 billion, a P/E ratio of -7.61 and a beta of 1.39.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on CLDX. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a report on Tuesday, May 6th. The Goldman Sachs Group lowered their price objective on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. UBS Group dropped their target price on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, Morgan Stanley lowered their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Celldex Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $53.90.
View Our Latest Report on CLDX
Celldex Therapeutics Profile
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Articles
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
